BRAF and plexiform neurofibroma: All patients were treated at the time of relapse or progression, except 17 patients (NF1-related plexiform neurofibroma treated by trametinib [10 patients]; BRAF-altered low grade glioma [LGG] treated by dabrafenib plus trametinib [4 patients]; NTRK fusion–positive sarcomas treated by larotrectinib [3 patients]).